PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.97%
EBIT growth below 50% of AXSM's 45.28%. Michael Burry would suspect deeper competitive or cost structure issues.
17.97%
Operating income growth under 50% of AXSM's 45.28%. Michael Burry would be concerned about deeper cost or sales issues.
18.43%
Net income growth under 50% of AXSM's 43.58%. Michael Burry would suspect the firm is falling well behind a key competitor.
58.16%
EPS growth 1.25-1.5x AXSM's 44.32%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
58.16%
Diluted EPS growth 1.25-1.5x AXSM's 44.32%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
96.23%
Share count expansion well above AXSM's 0.11%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
96.23%
Diluted share count expanding well above AXSM's 0.11%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
22.94%
OCF growth 1.25-1.5x AXSM's 18.81%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
22.94%
FCF growth 1.25-1.5x AXSM's 18.84%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-567.72%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.81%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
89.23%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-636.46%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
93.35%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
88.82%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
2271.09%
Equity/share CAGR of 2271.09% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-76.58%
Negative 5Y equity/share growth while AXSM is at 833.14%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-2.44%
Negative 3Y equity/share growth while AXSM is at 331.11%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
569.03%
Positive asset growth while AXSM is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
756.79%
Positive BV/share change while AXSM is negative. John Neff sees a clear edge over a competitor losing equity.
-16.19%
We’re deleveraging while AXSM stands at 0.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-15.49%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-24.67%
We cut SG&A while AXSM invests at 45.59%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.